Our Readers Write In - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Our Readers Write In

Pharmaceutical Technology

Can only fools use foolproof systems?

"We were a contract manufacturer that was proud of our warehouse control and computer inventory system from a well-known vendor," explains our Agent-In-Place. "Company management assured our clients and FDA that personnel had been adequately trained and that the control scheme was 'foolproof.'

"Things went smoothly until a data-entry clerk logging quarantined material into the system reversed two numbers: 57,282 items were received, but the number was entered as 52,782!

"When the warehouse manager reviewed the inventory, he noted that only a portion of the received materials had been quarantined. Because the other portion of the batch wasn't in quarantine, he assumed that the entire lot shouldn't have been in quarantine. He manually changed the inventory status of the entire lot from 'quarantined' to 'approved.' Before the lot had been formally evaluated and released, it was issued and used in manufacturing.

"Of course, when quality assurance inspected the lot, they found problems with it. Not knowing that some had already been used, they rejected the lot."

Foaming for release

"Our group had helped out in validating the new production line on an orally disintegrating tablet project, and dissolution results were typically greater than 95% active ingredient released in 10 minutes," notes our Agent-In-Place. "We had already settled in on the next project when a lot was rejected. The site noted that the dissolution testing of this lot showed low-release results that were also highly variable, which was unusual for the product.

"I was the dissolution specialist on the original project, so I went to the site to troubleshoot the method. As a starting point, I observed a repeat dissolution test being conducted on the lot in question. When the bath covers were removed, I found foam crawling up the paddle shafts.

"The quality control laboratory analyst was shocked when I sampled the foam and told me, 'That isn't in the method!' I replied, 'We have now moved from QC into R&D and investigation.'

Analysis of a sample of the foam showed high API content. It was known that the tablets were prone to foam formation, and a simethicone suspension was used to suppress foam in the manufacturing process. Further investigation into the simethicone suspension showed that the simethicone settles out if not agitated immediately before aliquoting to the batch, which apparently had not been done in this case. This allowed the tablets to melt into foam on the surface and prevent release of the API."

Critical melding point

"We have a large-volume parenteral that is filled into glass bottles," describes our Agent-In-Place. "The original product had metal slings attached directly to the bottles so that they could be hung up-side down to administer the product directly from the bottle. To improve the speed of packaging and lower the price of the package, we changed to a new plastic sling.

"But then, we started receiving complaints. Nurses reported to us sling breakage at the hanging location. Our investigation showed that the breakage was associated with a bad meld where the injected plastic met at the furthest point from the injected site. We ended up having to make another sling change, this time to a type that did not have the meld right at the most critical location."


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here